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ABSTRACT
In this study, we explored the applicability of using in vitro micronucleus (MN) data from human lymphoblastoid TK6 cells
to derive in vivo genotoxicity potency information. Nineteen chemicals covering a broad spectrum of genotoxic modes of
action were tested in an in vitro MN test using TK6 cells using the same study protocol. Several of these chemicals were
considered to need metabolic activation, and these were administered in the presence of S9. The Benchmark dose (BMD)
approach was applied using the dose-response modeling program PROAST to estimate the genotoxic potency from the
in vitro data. The resulting in vitro BMDs were compared with previously derived BMDs from in vivo MN and carcinogenicity
studies. A proportional correlation was observed between the BMDs from the in vitro MN and the BMDs from the in vivo MN
assays. Further, a clear correlation was found between the BMDs from in vitro MN and the associated BMDs for malignant
tumors. Although these results are based on only 19 compounds, they show that genotoxicity potencies estimated from
in vitro tests may result in useful information regarding in vivo genotoxic potency, as well as expected cancer potency.
Extension of the number of compounds and further investigation of metabolic activation (S9) and of other toxicokinetic
factors would be needed to validate our initial conclusions. However, this initial work suggests that this approach could be
used for in vitro to in vivo extrapolations which would support the reduction of animals used in research (3Rs: replacement,
reduction, and refinement).
Key words: in vitro micronucleus; TK6 cells, benchmark dose approach; genotoxic potency
Short-term genotoxicity tests are generally utilized in cancer
risk assessment in a qualitative manner for hazard identifica-
tion, but here we explored their applicability for quantitative
analysis and prediction of cancer potency. In vitro genotoxicity
assays are designed to detect a wide-range of different types of
genetic damage, where certain outcomes require follow-up test-
ing. For instance, in vivo genotoxicity tests may be performed
because they take into account factors such as toxicokinetic
and toxicodynamic processes, so that more relevant inferences
on the potential risk of chemical exposure in humans can be
made. The choice of follow-up in vivo tests depends on the type
of genotoxic damage detected from in vitro tests (ie, gene muta-
tions or chromosomal aberrations). Generally, an in vivo MN test
is often performed if the compound was found to induce chro-
mosomal aberrations in vitro. If there are indications that the
compound induces gene mutations in vitro, then the transgenic
rodent mutation assay is performed in potential target tissues
(Eastmond et al., 2009). Depending on the regulatory body, a
VC The Author 2015. Published by Oxford University Press on behalf of the Society of Toxicology.
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positive result in an in vivo (or in vitro) genotoxicity study can re-
sult in the substance to be forbidden as in the case for food ad-
ditives or can trigger a 2-year cancer bioassay to determine the
carcinogenic potential of substances, and/or for the derivation
of a point of departure (POD) for further risk assessment. A car-
cinogenicity study generally involves a 2-year exposure to a
chemical using 50 animals (rodents) per dose per sex with a
minimal of 3 doses (OECD, 2008). Shortcomings of the 2-year
cancer bioassay include the large number of animals used (typi-
cally 400 per species), the long time it takes to get the results,
and the high cost (1 to several million euros depending on
route of exposure; (Jacobson-Kram et al., 2004). Worldwide ef-
forts are being made to reduce the number of animals used in
research and, at the same time, satisfy regulatory requirements
in keeping the human population safe.
In Toxicity Testing in the 21st Century (NRC, 2007) the use of
novel data streams, such as in vitro mutagenicity data of DNA-
reactive chemicals is emphasized, as well as the need for devel-
oping the methodology for using them as primary data in
human hazard assessment. Several efforts are exploring the
possibility of quantitatively using data from genetic toxicology
studies for use in human health risk assessment (Gollapudi
et al., 2013; Hernandez et al., 2011, 2012; Johnson et al., 2014a,b;
MacGregor et al., 2014a,b; Soeteman-Hernandez et al., 2015).
These studies showed that in vivo genotoxicity studies provide
more information than just the presence or absence of geno-
toxic potential for a given compound. The doses required to
achieve a given genotoxic response in an in vivo MN test were
found to differ considerably among substances. These equipo-
tent doses, estimated as Benchmark doses (BMDs), were found
to correlate with the doses resulting in a given level of carcino-
genic response (Hernandez et al., 2012, 2012; MacGregor et al.,
2014a,b; Soeteman-Hernandez et al., 2015). These studies sug-
gest that the genotoxic potency assessed in an in vivo MN test
might be used as a predictor of the carcinogenic potency of the
same compound. This is conceivable given that the in vivo MN
test measures the induction of chromosomal aberrations, a pro-
cess that is generally considered to be strongly associated with
carcinogenesis (Bonassi et al., 2011). MN is commonly used as a
biomarker of chromosomal damage, genome instability, and
cancer risk in humans. There is preliminary evidence that MN
frequency in peripheral blood lymphocytes is predictive of can-
cer risk (Bonassi et al., 2011) and is used as an indicator of early
genetic effects for instance as a result of occupational exposure
to polycyclic aromatic hydrocarbons (Wang et al., 2012), pesti-
cides (Bolognesi et al., 2011) or in cancer patients (Iarmarcovai
et al., 2008) as a biological marker for the efficacy of a chemo-
preventive regime (Rosin, 1992).
In this study, we focus on the question to what extent in vitro
genotoxicity tests could provide information on the in vivo geno-
toxic and carcinogenic potency of chemicals. A preliminary
in vitro MN study with human lymphoblastoid (AHH-1) and
Chinese Hamster fibroblast (V79) cell lines showed that after
treatment with 17 -b-oestradiol (E2), bisphenol-A (BPA), and
Rotenone, the BMDL10s for in vitro MN and the most sensitive tu-
mor endpoint were in both cases ranked as E2>BPA>>Rotenone
(Hernandez et al., 2013). Even though these compounds are
aneugens and the number of compounds was only 3, these re-
sults provided a first indication of the applicability of this meth-
odology for the potential for deriving carcinogenic potency
information from in vitro MN studies. To further explore this, we
selected 20 compounds from those that were examined by
Hernandez et al. (2012) and Soeteman-Hernandez et al. (2015),
and for which a correlation was found between the in vivo MN
BMDs and the cancer BMDs. These 20 chemicals were subjected
to an in vitro MN tests using TK6 cell line, with the purpose of in-
vestigating whether they correlate with the earlier obtained
BMDs from in vivo MN tests and from carcinogenicity studies
(Hernandez et al., 2012). If BMDs from in vitro genotoxicity tests
could provide information on the carcinogenic potency of com-
pounds, this might be highly useful in improving test strategies
and in supporting the reduction of animals used in research
(3Rs: replacement, reduction, and refinement).
MATERIALS ANDMETHODS
Test Compounds
The list of 20 compounds that were tested in the in vitro MN test
is presented in Table 1, together with the abbreviations used in
this paperarticle. This table also shows the concentrations used
for each compound, and whether or not S9 (metabolic activa-
tion) was applied. The concentrations to be tested in each com-
pound, as well as the requirement for metabolic activation was
based on previously published genotoxicity and cytotoxicity
data and from range-finding experiments performed at
AstraZeneca UK (Figure Fig. 1). Although the chemicals chosen
were those already known to have yielded in vivo MN BMDs
that correlated well with tumor BMDs, as demonstrated in
Table 2, compounds selected also included those that were
equivalent or negative for in vivo MN (cbc, dmh, pge, and tce)
and for carcinogenicity (chl, hrc, and cps) using traditional
methods. In addition, there were 7 compounds (cop, dbe, dcn,
hrc, php, tet, and ure) that were negative in the in vitro MN and
positive in the in vivo MN, and one 1 compound (tce) was posi-
tive in the in vitro MN and negative in vivo MN using the pair-
wise statistical significance methods for defining positives and
negatives (Table 2).
In VitroMN Test
Metabolic activation (S9). For treatments in the presence of exoge-
nous metabolism, S9 from the livers of Aroclor 1254 treated rats
was purchased from Molecular Toxicology Inc. (Boone, North
CarolinaNC, USA) and stored frozen at a temperature of (-65C
or below until use. On the day of use, S9 mix was prepared by
the addition of culture medium containing cofactors for NADPH
generation to the S9 fraction. A final S9 concentration 2% vol/vol
was used.
Test agents. The test agents were dissolved in dimethyl
sulphoxide (DMSO) before use. All chemicals and reagents were
purchased from Sigma Aldrich. A list of compounds, abbrevia-
tions and the concentrations used are presented in Table 1.
N-Nitroso-N-Methylurea and benzo[a]pyrene were used as
positive controls.
Cell culture. The TK6 cell line (known in early publications as
H2BT) is a subclone of WI-L2 established in 1968 (Levy, 1968).
The cells used for this study were obtained as a gift from
Swansea University in 2009. In house karyotypic analysis in
2010 showed these TK6 cells to have a modal chromosome
number of 47 and a stable composite karyotype of 47 XY,
þder13t(13;22) -14 þder14t (14;20) der 21 (21,3) .
TK6 cells were routinely cultured in Roswell Park Memorial
Institute 1640 (RPMI) medium (Invitrogen, Paisley, UK)
supplemented with 10% heat-inactivated donor horse serum,
2 mmol/L l l-glutamine, 2 mmol/L l sodium pyruvate, 200 IU/mlL
penicillin, and 200 mg/mL ml streptomycin (R10). Cells were
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grown at 37C in a humidified atmosphere of 5% CO2 in air and
had an average doubling time of 15–16 hours. Cells were gener-
ally maintained at between approximately 2 x 104 and 1x
106 cells//mlL (Molloy et al., 2010).
Treatment. All the in vitro MN tests were performed in the same
lab. Treatment exposure was for 3 h in the presence or absence
of S9 as appropriate for each test agent. 1 106 TK6 cells were
suspended in 4 ml RPMI, containing 2.5% heat-inactivated
donor horse serum. The test compound or solvent control solu-
tions were added at 1% vol/vol. Quadruplicate solvent control
and duplicate test compound cultures were prepared. Following
treatment, the cells were centrifuged, washed once, and resus-
pended in R10 at a final cell concentration 1 105 cells/ml.
Cultures were incubated for approximately 40 h. Microscope
slides were prepared by centrifuging at least 1 105 cells in a
Cytospin 3 (ShandonTM) centrifuge (800 rpm [100 g] for 8 min)
and fixed with methanol. Slides were stained with acridine
orange. All identified MN were confirmed by eye to be separate
and within the cytoplasm, to have intact cytoplasmic
membrane and to be less than one-third of the diameter of the
main nucleus. Where possible, a total of at least 1000 cells per
culture were scored. The response for dose-response analysis
was %cells with MN. In Table 2, in vitro MN positives are shown
based on pairwise statistical significance testing with a P< .05.
Table 3 summarizes the experimental design from the
in vitro MN.
Cytotoxicity. For each treatment cytotoxicity was determined by
calculation of a reduction in relative population doubling (RPD).
Cell number was assessed on the day of sampling (1 day after
treatment). Cultures giving RPD of less than 45% were consid-
ered to be excessively cytotoxic. This is in accordance with the
suggested percent toxicity of 55%6 5% in the recent study by
Sobol et al. (1995) regarding the development and validation of
an in vitro MN platform in TK6 cells (OECD, 2014).
RPD was determined as:
Number of Population doublings in treated cultures
Number of Population doublings in control cultures
 100
TABLE 1. List of Compounds, Abbreviations, Study Number, and Concentrations Tested
Compound Abbreviation Cas. No. Concentration (ug/ml) S9
2-Acetylaminofluorene aaf 53-96-3 0, 14, 28, 56, 112, 223 Yes
2-Acetylaminofluorene aaf 0, 14, 28, 56, 112, 223 Yes
Benzo(a)Pyrene bap 50-32-8 0, 0.16, 0.32, 0.63, 1.3, 2.5, 5 Yes
Benzo(a)Pyrene bap 0, 0.16, 0.32, 0.63, 1.3, 2.5, 5 Yes
Chlorambucil cbc 305-03-3 0, 0.00913, 0.0304, 0.0913, 0.304, 0.913 No
Chlorambucil cbc 0, 0.00913, 0.0304, 0.0913, 0.304, 0.913 No
Chloral Hydrate chl 302-17-0 0, 103, 207, 414, 827, 1654 No
Chloral Hydrate chl 0, 103, 207, 414, 827, 1654 No
4-Chloro-o-phenylenediamine cop 95-83-0 0, 1.8, 3.6, 7.1, 14, 29, 57 No
4-Chloro-o-phenylenediamine cop 0, 1.8, 3.6, 7.1, 14, 29, 57 No
Cyclophosphamide cpa 50-18-0 0, 0.028, 0.084, 0.28, 0.84 Yes
Cyclophosphamide cpa 0, 0.028, 0.084, 0.28, 0.84, 2.8 Yes
P,P – dichlorodiphenyl sulfone cps 80-07-9 0, 2.24, 4.48, 8.97, 18, 36, 72 No
P,P – dichlorodiphenyl sulfone cps 0, 2.24, 4.48, 8.97, 18, 36, 72 No
1,2-Dibromoethane dbe 106-93-4 0, 12, 23, 47, 94, 188, 376 No
1,2-Dibromoethane dbe 0, 12, 23, 47, 94, 188, 376 No
Decalin dcn 91-17-8 0, 3.5, 7, 14, 28, 41, 55 No
Decalin dcn 0, 3.5, 7, 14, 28, 41, 55 No
1-2 Dimethylhydrazine dmh 306-37-6 0, 0.06, 0.018, 0.6, 0.18, 60, 180 No
1-2 Dimethylhydrazine dmh 0, 0.06, 0.018, 0.6, 0.18, 60, 180 No
Chloroform for 67-66-3 0, 1.19, 3.57, 11.9, 35.7, 119, 357 No
Chloroform for 0, 1.19, 3.57, 11.9, 35.7, 119, 357 No
Glycidol gly 556-52-5 0, 4.625, 9.25, 19, 37, 74, 148 No
Glycidol gly 0, 4.625, 9.25, 19, 37, 74, 148 No
4-Hexylresorcinol hrc 136-77-6 0, 2.4, 4.9, 9.78, 13, 16 No
N-Nitro-N-Methylurea mnu 684-93-5 0, 0.0031, 0.0103, 0.031, 0.103, 0.31 No
N-Nitro-N-Methylurea mnu 0, 0.0031, 0.0103, 0.031, 0.103, 0.31, 1.03 No
4-Chloroaniline hydrochloride pch 20265-96-7 0, 49.2, 164, 492 No
4-Chloroaniline hydrochloride pch 0, 4.92, 16.4, 49.2, 164, 492 No
Propylene Glycol Mono-T-Butyl Ether pge 57018-52-7 0, 3.96, 13.2, 39.6, 132, 1320 No
Phenolphthalein php 77-09-8 0, 9.54, 31.8 No
Phenolphthalein php 0, 9.54, 31.8 No
Phenolphthalein php 0, 7.96, 16, 32 No
Trichloroethylene tce 79-01-6 0, 3.94, 13.1, 39.4, 131, 394 Yes
Trichloroethylene tce 0, 3.94, 13.1, 39.4, 131, 394 Yes
1,1,2,2-Tetrachloroethane tet 630-20-6 0, 11, 21, 42, 84, 168, 336 No
1,1,2,2-Tetrachloroethane tet 0, 11, 21, 42, 84, 168, 336 No
Urethane ure 51-79-6 0, 111, 223, 445, 891 No
Urethane (ure) ure 0, 111, 223, 445, 891 No
Each row represents a replicate.
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where
Population Doubling ¼
½log ðcell number on day of sampling=initial cell numberÞ
log 2
The raw data are provided in the Supplementary Table 1.
BMD analysis. BMDs associated with the same benchmark
response (BMR) (related to the same endpoint) are equipotent
doses, and can thus be used to rank potencies of different com-
pounds. In this article, the term potency is used in a relative
sense only, and is not defined in an absolute sense (such as the
“slope factor” in an LMS model fitted to cancer data).
BMD analysis was performed using PROAST, a dose-
response modeling software package developed at the National
Institute for Public Health and the Environment (RIVM) in the
Netherlands (www.proast.nl). The genotoxicity data (% cells
with MN out of 1000 cells scored) were analyzed as continuous
data, and the 4-parameter exponential model was fitted to
these data.
BMD analysis was performed on the in vitro MN data that
were newly generated in this study. Similar to Hernandez et al.
(2012) and Soeteman-Hernandez et al. (2015), the in vitro MN
data were analyzed as one combined dataset, where compound
was included as a covariate. The in vivo MN data, earlier ana-
lyzed in Soeteman-Hernandez et al. (2015), were reanalyzed tak-
ing compound as a covariate, as opposed to using individual
dataset as a covariate. The compounds were found to differ sig-
nificantly in background response (due to study differences)
and potency (due to the compound differences), but otherwise
the shape of the dose-response among different chemicals was
found to be similar. The latter is a general phenomenon in toxi-
cological dose-response data (Slob and Setzer, 2014), and was
confirmed for the new in vitro MN data in this study (see Fig. 1).
Fitting a single model to the combined dataset (with compound
as covariate) results in smaller BMD confidence intervals as
compared with fitting the model to each compound separately
(Slob and Setzer, 2014). We did not take into account potential
differences among replicate studies in the same compound (as
available for part of the compounds, see Table 1). This means
that the estimated dose-response for each compound (and
FIG. 1. Best fitting curves for each compound, resulting from a fitted (4-parameter) exponential model to the combined dataset assuming that each compound had its
own background response and potency, but that the shape parameters are the same among compounds. For each compound, a BMD was derived with respect to its
control. The vertical dashed line indicates the BMD05 (lg/ml) for the fitted curve. x-axes represent log10 of dose (scaled to obtain dose ¼ 1 as being the maximum dose
value, for numerical reasons). Controls are plotted at the value 6. y-axes represent log10 of fraction (%) of micronuclei in 1000 cells scored. The circles represent the
geometric mean of the percent in vitro micronucleus for each concentration tested. Abbreviation: BMD, Benchmark dose.
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hence the BMD) reflects an average of the replicate studies in
the same compound.
The BMD results for the in vivo MN and the carcinogenicity
dose-response data were obtained from Hernandez et al. (2012)
and Soeteman-Hernandez et al. (2015). However, the in vivo MN
data were re-analyzed with compound rather than individual
dataset as a covariate. In this way, a single potency estimate
(BMD confidence interval) was obtained for each compound,
reflecting the average estimate over different dose-response
datasets for that chemical, eg, relating to the 2 sexes, or the 2
tissues evaluated (blood, bone marrow).
It is important to note that, for the purpose of correlating
in vitro MN potency to in vivo MN potency (or cancer potency),
equipotent doses should not be estimated as single point esti-
mates (BMDs) but rather as BMD confidence intervals, for vari-
ous reasons. First, the BMD is only an estimate with a certain
precision that may be good or poor, depending on the chemi-
cal’s dataset. Thus, a point that appears to be an outlier in the
correlation plot could be so for biological reasons or simply
because that point was an imprecise estimate. This distinction
can be made visible by considering BMD confidence intervals
rather than single BMD values. Another reason is that, in this
way, compounds showing no or only a weak dose-response do
not need to be omitted but can be taken into account in the
analysis. These compounds will have a confidence interval with
a finite lower bound and an infinite (or very large) upper bound.
This interval tells us that the dose where the response is equal
to the equivalent effect size (BMR) will be larger than the lower
bound of the confidence bound (called BMDL). In other words,
the specified increase in MN (¼BMR) will not likely occur at a
dose lower than the lower BMD confidence bound (¼BMDL).
Replacing such an infinite confidence interval with a single esti-
mate of the BMD would be misleading, and not represent the
information that is available for that dataset.
Choice of BMR. For deriving (equipotent) doses, it can be expected
that the value of the BMR is not essential (as long as it is the
same for all chemicals in the group). The reason is that the stat-
istical analysis assumed the dose-responses to be parallel
(against log-dose). This theoretical notion is confirmed by
Bemis et al. (2015) who calculated BMD confidence intervals for
various values of the BMR, resulting is similar correlations. We
used a BMR of 5% change in mean response as compared with
the controls, as this value was also used for the BMDs from the
in vivo MN tests in our earlier study (Soeteman-Hernandez et al.,
2015) and it is also a recommended BMR for continuous
response data by the European Food Safety Authority (EFSA,
2009a,b). Just like this earlier study we used a BMR of 10% extra
risk for carcinogenicity studies used because it is the most com-
monly used value of the BMR in dose-response characterization
of quantal endpoints (EFSA, 2009a,b). When the BMDs in both
systems are proportionally correlated (as will appear to be the
case in our results) changing the BMR would only affect the pro-
portionality constant (shift the correlation line), without chang-
ing the correlation (scatter around the line) as such.
It may be noted that the BMR for continuous data can also be
defined in terms of the SD, the standard deviation of the within
group variation. A BMR as a percentage change appears to better
reflect the biological change in MN needed for an increased can-
cer risk than the BMR in terms of the within group SD. The latter
TABLE 2. Outcome of Tests Using the Traditional Methods for Determining a Positive Response in the In Vitro and In Vivo MN and
Carcinogenicity Studies
Compound In Vitro MN In Vivo MN Cancer Source Cancer IARC Mode of Action
aaf þ þ1 þ CPD  Mutagenic hepatocarcinogen8
bap þ þ2,3 þ CPD 1 Mutagenic9 and clastogenic10 carcinogen
cbc þ e4 þ CPD 1 Mutagenic11 carcinogen
chl þ þ e TR-502 3 Aneugenic12 carcinogen (interferes with tubulin assembly
and shortens microtubules)
cop E þ þ TR-063 2B Mutagenic13 carcinogen
cpa þ þ5,6 þ CPD 1 Clastogenic10 carcinogen
cps þ þ  TR-501  Noncarcinogen14
dbe E þ þ TR-086 2 A Mutagenic15 carcinogen
dcn  þ þ TR-513  Mutagenic16 carcinogen (rat kidney specific, alpha2u-globulin)
dmh þ e7 þ CPD 2A Mutagenic17 and clastogenic18 carcinogen
for þ þ þ TR-000 (67-66-3) 2B Nongenotoxic19 carcinogen (cytotoxicity and regenerative
hyperplesia)
gly þ þ þ TR-374 2A Mutagenic and clastogenic20 carcinogen
hrc  þ e TR-330  Noncarcinogen21
mnu þ þ þ CPD 2A Mutagenic and clastogenic22 carcinogen
pch þ þ þ TR-351  Noncarcinogen23
pge   þ TR-515 3 Nongenotoxic24 carcinogen (alpha2u-globulin)
php  þ þ TR-465 2B Clastogenic25 carcinogen
tce þ  þ TR-002 2A Nongenotoxic26 carcinogen (peroxisome proliferator/tumor
promoter27)
tet  þ þ TR-027 3 Weak mutagenic28,29 carcinogen
ure  þ þ TR-510 2A Mutagenic30 carcinogen
IARC, International Agency for Research on Cancer; CPD, carcinogenic potency database (http://potency.berkeley.edu/); MN, hematopoietic MN test; AB, abbreviation;
TR, National Toxicology Program technical report; þ, positive; , negative; e, equivocal. 1(Asano and Hagiwara, 1992); 2(Vrzoc and Petras, 1997); 3(Shimada et al., 1992);
4(Morita et al., 1997); 5(Gorelick et al., 1999); 6(Hatanaka et al., 1992); 7(Meli and Seeberg, 1990); 8(Heflich and Neft, 1994); 9(Benford et al., 2010); 10(Sobol et al., 2012);
11(Mohamed et al., 2009); 12(Fellows et al., 2011); 13(Staedtler et al., 1999);14(NTP, 2001); 15(Liu et al., 2007); 16(NTP, 2005); 17(Newell and Heddle, 2004); 18(Ashby and Mirkova,
1987); 19(Butterworth et al., 1998); 20(Ikeda et al., 2012); 21(NTP, 1988); 22(Johnson et al., 2009); 23(NTP, 1989); 24(NTP, 2004); 25(NTP, 1996); 26(Wilmer et al., 2014); 27(Tabrez
and Ahmad, 2009); 28(Colacci et al., 1989); 29(McGregor et al., 1988); 30(Hernandez and Forkert, 2007).
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definition of a BMR is subject to coincidental experimental het-
erogeneity or errors, including measurement errors (in the case
of MN depending on the number of cells counted) A BMD for a
given percent change is less sensitive to experimental condi-
tions and errors, and appears a better measure for comparing
equipotent doses/concentrations across endpoints (Johnson
et al., 2014b).
Dose-response analysis. Dose response analysis was performed
similarly as previously published (Soeteman-Hernandez et al.,
2015). Briefly, for “continuous” dose-response data from the
in vitro and in vivo MN test, data were analyzed by fitting the
exponential model, which is one of the recommended models
for continuous data (EFSA, 2009a,b) and known to be generally
applicable to toxicity data:
y ¼ a c c 1ð Þexp bxd
 h i
where y is the response (proportion of cells with MN) and x the
dose. In fitting the model to the combined cluster of datasets,
separate values for a (reflecting the background response at
dose 0) and b (reflecting the potency of the chemical) are esti-
mated for each compound in the dataset, whereas parameters c
and d are kept constant over all datasets within the cluster ana-
lyzed. The within group variance was estimated separately for
each compound as well. Please refer to Slob (2002) or Slob and
Setzer (2014) for a more detailed discussion of this method.
For the “quantal” dose-response data from the carcinogenic-
ity studies the log-logistic model was fitted.
y ¼ aþ ð1  aÞ
1 þ exp½c logðx=bÞ
where y is the response (fraction of affected animals) and x the
dose. Again, parameters a (reflecting the background response
at dose zero), and b (reflecting the potency of the chemical) are
estimated for each individual dose-response dataset, whereas
(shape) parameter c is kept constant over all datasets within the
analyzed cluster (See Soeteman-Hernandez et al. [2015] for more
details).
Examining correlations between systems. The usual way of quanti-
fying a correlation is by deriving a correlation coefficient.
However in our case, a substantial part of the chemicals
resulted in one-sided infinite confidence intervals. Those chem-
icals definitely need to be included in examining the correla-
tion, as they represent (in most cases) the weakly potent
chemicals. These chemicals may provide important informa-
tion: a weak potency in 1 system being associated with a high
potency in the other would mean that this chemical does not
comply with the overall correlation, which may have biological
significance. Instead, correlation plots (in vitro MN vs in vivo MN
in Fig. 2 and in vitro MN vs carcinogenicity in Fig. 3) were created
by plotting their CIs (in both the x- and y-direction) related to
matching chemicals, including the ones that resulted in
(1-sided) infinite CIs. Inside the correlation plots we plotted a
dashed box, indicating the largest finite BMDU (and lowest
BMDL) of all intervals assessed, so that it is directly visible
which CIs have infinite bounds (ie, when they cross outside the
dashed box). As already noted, a deviating value (BMD) might be
the result of low precision in a test system, and to make that
possibility visible, the correlation between BMDs needs to be
examined based on the complete BMD confidence intervals,
taking both the lower (BMDL) and upper bound (BMDU) into
account.
Instead of calculating a correlation coefficient we evaluated
the observed correlations in another way. The BMDs in the 2
systems were plotted against each other on double-log scale. A
linear relationship (with intercept zero) on the original scale
translates into a straight line with unity slope in a double log-
plot. Therefore, we drew 2 lines with unity slope (in the double
log-plots) such that they encompass most of the BMD confi-
dence intervals. If the individual chemicals are more or less ran-
domly located between these 2 lines, this indicates that the
relationship between the BMDs on y- and x-axis is (approxi-
mately) linear, in the sense that their values differ by a propor-
tionality constant. Further, the vertical distance between both
lines reflects an uncertainty margin related to the prediction of
the BMD on the y-axis based on a given BMD on the x-axis. For
instance, our previous analysis (Soeteman-Hernandez et al.,
2015) showed that the cancer BMD can be predicted within
around 2 orders of magnitude from a given value of the in vivo
MN BMD. This uncertainty margin is in fact a measure of corre-
lation: the better the correlation, the smaller the uncertainty
margin. This visual way of establishing the correlation will suf-
fice for the time being, as we are mainly interested in the ques-
tion if information from in vitro or in vivo genotoxicity tests can
at all be useful for predicting carcinogenic potency, and if so, for
which type of chemicals (modes of action). A formal method for
estimating the precision in that prediction may be developed at
a later stage.
RESULTS
All of the in vitro MN TK6 dose-response data were analyzed as a
single combined dataset using compound as a covariate,
assuming that compounds differed in background response
(due to different studies) and in potency, but not in the shape of
the dose-response. The resulting curves associated with the fit-
ted model to the combined dataset are individually shown for
each compound in Figure 1. Visual inspection of the plots shows
that the assumption of equal shapes was not violated, except
possibly for the compound chlorambucil (cbc), where the
observed response at the highest dose is not well described by
the fitted curve. However, this dose group could also be an
“outlier,” ie, the particular dose group might have differed from
the other treatment groups in that study by some unknown
experimental factor other than the dose (see Slob and Setzer,
2014, for a discussion of dose group outliers).
For most compounds 2 replicate studies were available. It
was found that in some cases the dose-responses were some-
what dissimilar. In the analysis shown in Figure 1 this was
ignored, and the BMD confidence intervals for each compound
should thus be regarded as relating to the compound’s potency
averaged over the 2 replicated studies.
From the 20 compounds with in vitro MN dose-response
data, only 1 (the compound “tet”) resulted in a 2-sided
unbounded confidence interval (meaning that the data are not
informative enough to even decide whether the compound is
very potent or not potent at all). Such an interval does not pro-
vide any information on the equipotent dose, and it was deleted
in further analyses. From the remaining 19 compounds, 9
showed (2-sided) finite confidence intervals and 10 showed con-
fidence intervals with an infinite upper bound (see Table 4). It is
important to note that almost all the derived in vitro MN
BMDL05 values (Table 4) were at concentrations where cytotox-
icity was>90%.
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In Vivo Versus In Vitro MN
Table 3 summarizes the experimental design from the in vivo
MN studies. Table 4 shows the BMD confidence intervals for the
in vitro MN studies against those for the in vivo MN studies on
the same chemicals. Figure 2 shows the same results graphi-
cally. Note that decreasing values for the BMD indicates increas-
ing potency. A proportional relationship between the BMDs in
both systems translates into a line with unity slope in a double-
log plot. The 2 parallel dashed lines in Figure 2 are unity slope
lines drawn by eye. This indicates that, overall, the in vivo BMD
approximately relates proportionally to the in vitro BMD. The
distance between the 2 dashed lines in the vertical direction is 2
log10 units. Hence, the uncertainty in predicting the in vivo BMD
from the in vitro BMD approximately would be somewhat more
than 2 orders of magnitude (as some of the chemicals are just
outside the 2 dashed lines). None of the 19 chemicals was found
in the more extreme top-left or bottom-right areas of the plot,
ie, no chemicals were found with low potency the in vitro and
high potency in the in vivo MN test, or vive versa.
Carcinogenicity Versus In Vitro MN
Table 3 summarizes the experimental design from the carcino-
genicity studies. Figure 3 shows the correlation between the
in vitro BMD confidence intervals and the cancer BMD confi-
dence intervals earlier obtained from carcinogenicity studies
(Soeteman-Hernandez et al., 2015). For 2 of the chemicals tested
in the in vitro MN test (dmh, mnu) no adequate tumor BMDs
could be derived (due to short exposure durations in the avail-
able carcinogenicity studies in both dmh and mnu, and lowest
dose with high response in dmh). When incidence data related
to various types of lesions were available in the same com-
pound, we first selected the datasets related to malignant
tumors observed in a single tissue (if available), and from those
we selected the one resulting in the lowest BMD. The rationale
for focusing on a single type of cancer lesions is that BMDs asso-
ciated with different types of lesions (reflecting different stages
of the carcinogenicity process) may not represent equipotent
doses, which is essential for the research question here as with
our previous study (Soeteman-Hernandez et al., 2015). Given
that in vivo MN potencies were found to correlate with cancer
potencies (Soeteman-Hernandez et al., 2015), the correlation
found in Figure 3 was not unexpected. For the 9 compounds
with finite BMD confidence intervals resulting from the in vitro
MN test, the correlation with the tumor BMDs is good. For the 10
chemicals resulting in in vitro BMDs with infinite upper bounds
the associated tumor BMDs had finite BMD CIs. Because the lat-
ter were in the higher end of the range (ie, low potency) their
exact relative position could not be predicted based on the
in vitro potency. All that they could predict was that the cancer
potency would be relatively low. The 2 parallel sloped lines
roughly encompass the observed BMD confidence intervals as
found in the test chemicals. By taking the lowest intersection
point with the left vertical line and the highest intersection
point with the right vertical line we obtain the uncertainty
range for the predicted BMD10 for carcinogenicity (see the 2
plotted circles in Fig. 3). In this way, both the prediction uncer-
tainty related to the scatter in the correlation and the uncer-
tainty in the BMD on the x-axis is taken into account.
DISCUSSION
Genetic toxicity studies have been generally used in a qualita-
tive yes/no fashion to assess whether a compound is genotoxic
or not. However, recent efforts have explored ways of quantify-
ing the compound’s genotoxic potency by examining suitable
metrics based on dose-response analysis of genotoxicity
FIG. 2. BMD confidence intervals for in vivo MN studies against those for in vitro MN studies. In both types of studies the BMD relates to BMR¼ 5%. The x-axis represents
log10 of concentration in mg/ml, the y-axis log10 of dose in mg/kg/day. The 2 parallel lines have a slope 1, and were drawn by eye such that they span 2 orders of magni-
tude in vertical direction. See Table 1 for abbreviations of the associated individual compounds. Abbreviations: BMD, Benchmark dose; MN, micronucleus.
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data. The BMD approach was shown to be a suitable method
for examining in vitro and in vivo genotoxicity studies for methyl
methanesulfonate (MMS), ethyl methanesulfonate (EMS),
1-methyl-1-nitrosourea (MNU) and 1-ethyl-1-nitrosourea (ENU)
(Gollapudi et al., 2013; Johnson et al., 2014b). In this study, we
applied the BMD approach for estimating equipotent doses in
in vitro MN tests. By correlating these in vitro BMDs to cancer
BMDs we found a first indication that not only in vivo MN tests
provide useful information on the carcinogenic potency of com-
pounds (Johnson et al., 2014b), but that this may also hold for
in vitro MN tests in TK6 cells. It is evident that data for more
compounds are needed, including those that are mutagenic
rather than clastogenic, that are generally negative for in vivo or
in vitro MN yet are carcinogens, that require metabolic activa-
tion, and non-carcinogens. Nevertheless, we have shown that
potency information can be obtained from the in vitro MN test in
TK6 cells, and further research is warranted to further validate
our findings.
In general, the BMD confidence intervals resulting from the
in vivo studies are smaller than those from the in vitro studies
(Fig. 3). In particular, there were 6 chemicals that resulted in an
infinite BMD upper bound in the in vitro studies, but in a finite
BMD upper bound in the in vivo studies (Table 4 and Fig. 2).
These results indicate that the (current) in vivo MN test is more
sensitive in the statistical sense: the probability of detecting
compounds with relatively weak genotoxicity potency is greater
in the in vivo MN study than in the in vitro MN studies in TK6
cells. This could be due to differences in study design. For exam-
ple, the number of replicates in the in vivo MN tests used for
in vivo BMDs was usually larger than that in the in vitro tests as
performed in the present study.
Normally, it may be expected that much of the observed
scatter in Figure 2 is due to the fact that the in vitro test does not
account for the toxicokinetic processes (absorption, distribu-
tion, metabolism, and elimination) that may be relevant for
evoking the genotoxic response in vivo. Note that toxicokinetic
processes could have an impact in both directions. For example,
metabolic activation may result in a relatively high potency
in vivo, whereas limited absorption after oral exposure could
lead to relatively low in vivo potency, as compared with in vitro.
Piersma et al. (2008) used toxicokinetic information to evaluate
the observed scatter when correlating in vivo to ex vivo reproduc-
tive BMDs, illustrating that toxicokinetic information could be
used in a further analysis of the correlation between in vivo and
in vitro BMDs. However, for many of the 19 compounds compris-
ing the correlation plot in Figure 2 very little (quantitative) toxi-
cokinetic information is available, and an analysis as performed
by Piersma et al. (2008) was not feasible. However, it is likely
that toxicokinetic information could explain part of the scatter
in Figure 2.
Given the correlation that was found between the BMDs
from the in vitro and the in vivo MN test, and given the earlier
reported correlation between in vivo MN and cancer BMDs
(Hernandez et al., 2012), it could be expected that the BMDs from
the in vitro MN would also correlate to the cancer BMDs. As
shown in Figure 3, such a correlation was indeed present for the
17 compounds for which adequate data were available (for 2 of
the 19 chemicals no suitable carcinogenicity data were avail-
able). The compound urethane (ure) seems to deviate most
from the overall correlation scatter. Urethane is negative in
mammalian cells (mouse lymphoma assay and in vitro MN stud-
ies) and it remains uncertain as to whether urethane an Ames
positive compound is given that this has never been confirmed
(Kirkland et al., 2014). Although metabolism via CYP2E1 is
FIG. 3. BMD10 confidence intervals from carcinogenicity studies (lowest found
for malignant tumors in a single tissue) against BMD05s from in vitro MN test.
The latter are the same as those in Figure 2. The x-axis represents log 10 of con-
centration in mg/ml, the y-axis log10 of dose in mg/kg/day. The 2 parallel lines
roughly encompass the observed BMD confidence intervals as found in the test
chemicals. By taking the lowest intersection point with the left vertical line and
the highest intersection point with the right vertical line we obtain the uncer-
tainty range for the predicted BMD10 for carcinogenicity (see the 2 plotted
circles). In this way, both the prediction uncertainty related to the scatter in the
correlation and the uncertainty in the BMD on the x-axis is taken into account.
See Table 1 for abbreviations of the associated individual compounds.
Abbreviation: BMD, Benchmark dose.
TABLE 4. BMD05 Confidence Intervals for In Vitro and In Vivo MN
Tests and BMD10 Confidence Intervals for Cancer per Compound
Compound In Vitro MN
Test (mg/ml)
In Vivo MN Test
(mg/kg/day)
Cancer
(mg/kg/day)
BMDL BMDU BMDL BMDU BMDL BMDU
aaf 0.85 5.9 26.9 44.0 2.7 3.4
bap 0.006 0.04 0.001 2.36 0.9 1.3
cbc 0.0022 0.031 0.06 0.8 0.08 0.25
chl 82.4 Inf 360 1507 49.7 198
cop 21.1 Inf 55.8 166 522 960
cpa 0.0037 0.027 3.20 7.601 0.3 1.1
cps 4.39 Inf 32.3 296 30.4 66.0
dbe 8.36 83.9 5.96 47.2 12.3 16.7
dcn 9.03 Inf 723 Inf 381 1148
dmh 5.31 38.4 4.125 8.53 NA NA
for 72.7 Inf 270 1184 169 347
gly 3.73 21.2 141 237 21.5 32.5
hrc 4.47 Inf 67.6 Inf 71.1 187
mnu 0.0031 0.023 0.633 2.27 NA N/A
pch 20.2 108 32.1 122 16.3 41.3
pge 70.5 Inf 2780 Inf 1103 3167
php 7.92 Inf 478 715 567 1187
tce 26.8 Inf 10249 Inf 230 378
ure 163 Inf 43.2 74.6 7.5 15.2
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required, no evidence for mutagenic activity was reported with
urethane when S9 from rats induced with CYP2E1 was used in
the Ames test (Burke et al., 1994). It is not clear why urethane is
“missed” by mammalian cell tests (Kirkland et al., 2014).
There are several ways of performing in vitro to in vivo
extrapolations. One approach focuses on biokinetic modeling
with the purpose of relating to make appropriate adjustments
for binding and other factors affecting the free concentration of
the compound and converting the associated in vitro concentra-
tion into human equivalent in vivo concentrations (Blaauboer,
2010; Yoon et al., 2014). This approach is applicable when suffi-
cient toxicokinetic information with regards to the substance in
question is available. For cases where such chemical-specific
toxicokinetic information is not available, one may adopt
another approach and try to find empirical relationships
between in vitro concentrations and in vivo doses, as we did in
this study. For instance, Walum et al. (2005) established a rela-
tionship between in vitro cytotoxic concentrations and in vivo
acute lethal doses using 50 reference substances, and showed a
high predictability of in vitro cytotoxic concentrations for
human acute toxic doses. A similar approach was taken by the
Registry of Cytotoxicity database assembled by the Federal
Institute for Risk Assessment (BfR) which contains in vitro IC50
values and rodent LD50 values for a total of 347 substances.
Spielmann et al. (1999) analyzed these data and showed that the
IC50 values could be used for predicting the LD50 value. The
Interagency Coordinating Committee on the Validation of
Alternative Methods (ICCVAM) recommended the correlation
model from Spielmann et al. (1999) as a tool for predicting an
LD50 value to be used as a starting dose for the Acute Toxic
Class method (TG 423) or the Up-and-Down Procedure (TG 425).
Computer simulations showed that using in vitro cytotoxicity
assays to estimate an LD50 as a starting dose could potentially
reduce animal use by 28% for acute oral toxicity testing, and by
50% for nonclassified substances (ICCVAM, 2006; OECD, 2010).
We foresee that in vitro genotoxicity test may have a similar
impact and applicability.
Predicting Potencies Based on Correlations Between Systems
To illustrate how a BMD (and its uncertainty range) in 1 system
can be predicted from the BMD in the other system, and how
this might be used in risk assessment, consider a hypothetical
chemical X found in a food product. An in vitro MN test is avail-
able for this chemical, indicating that it is genotoxic. A risk
manager is interested in the cancer risk for consumers of the
contaminated food product. However, neither a carcinogenicity
study nor an in vivo genotoxicity study is available for that
chemical. The lower and upper intersection points of the verti-
cal lines with the sloped lines (indicated by the circles in Fig. 3)
may be considered as the lower and upper bound of the uncer-
tainty range for the predicted cancer BMD10. Here, the 2 sloped
lines have intercepts—0.5 and 2 on the log-scale, so the lower
and upper bound are 100.5¼ 0.32, and 102.4¼ 250 mg/kg, respec-
tively. Thus, the BMD10 for carcinogenicity is predicted to be
somewhere in the range between 0.32 and 250 mg/kg/day. This
result could be used as a reference for deriving a Margin of
Exposure between the lower/upper bound of the predicted BMD
for carcinogenicity and the estimated exposure in the human
subpopulation. If the margin of exposure (MOE) with the lower
bound of the predicted BMD is much larger than 10 000 it might
be concluded that there is no reason of concern (Barlow et al.,
2006). If the MOE with the upper bound of the predicted BMD
would be smaller than 10 000 this would indicate a reason of
concern. In intermediate cases, a conclusive answer might not
be possible. This illustration demonstrates one possible applica-
tion of this methodology in instances where risk management
need to make cancer-risk related decisions in the absence of
carcinogenicity data.
Limitations
This proof of concept approach informs only with regards to the
POD but does not inform on the subsequent steps needed for
the derivation of an acceptable risk of chemicals for humans.
There are currently many discussions on how different the low-
dose extrapolation approaches with the same POD can lead to
very different lower acceptable exposure levels. Acceptable
exposure levels can be orders of magnitude apart depending on
whether the linear low-dose cancer slope factor approach was
used or the threshold reference dose/uncertainty approach.
Mode of action information is therefore crucial for identifying
compounds with modes of action not considered to be directly
DNA reactive such as cytotoxicity (for in Table 2) where a non-
linear threshold approach is applicable, instead of a linear
approach (Butterworth et al., 1998). Mode of action can also
inform with regards to human relevance as seen with rodent-
specific peroxisome proliferators (tce in Table 2) (Wilmer et al.,
2014), and alpha2u-globulin-rat kidney specific tumors (dcn and
pge in Table 2) (NTP, 2004, 2005). There are also examples where
mode of action could be the same, such as MNU and ENU, both
being DNA reactive alkylating agents, however the potency,
DNA adduct spectrum and mutation spectrum are different, so
more detailed mechanism of action information may be
required (Doak et al., 2007; Johnson et al., 2009, 2014b). The
in vitro MN can distinguish between aneugens and clastogens if
methods such as fluorescence in situ hybridization are included
in follow-up work (Hernandez et al., 2013). The in vitro MN alone
is insufficient for a short-term strategy. Nevertheless, we fore-
see our approach being part of an integrated in vitro high
throughput screening strategy, as outlined in Toxicity Testing in
the 21st Century (NRC, 2007), where mode action and human
relevance information can be supplemented by other in vitro
screening methods and reducing animal testing.
Overall, we provide a proof-of-principle of the applicability
of using in vitro MN data for predicting the in vivo genotoxic
potency of a compound, as well as for predicting the cancer
potency of a compound. This finding warrants further research
with larger sets of compounds, with various MOAs. We are cur-
rently collaborating with international government agencies
(Health Canada, US FDA) and international organizations (ILSI/
HESI GTTC) to expand our database with more chemicals and to
refine the methodology. The server www.MutAIT.org has been
established as a data repository for collecting in vitro and in vivo
genotoxicity and carcinogenicity data.
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